The Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Impaired Glucose Tolerance

This study has been completed.

Sponsor:

Collaborator:

Lund University

Information provided by:

Skane University Hospital

ClinicalTrials.gov Identifier:

NCT01027585

First received: December 7, 2009

Last updated: NA

Last verified: May 2009

History: No changes posted

Tracking Information

First Received Date ^ICMJE

December 7, 2009

Last Updated Date

December 7, 2009

Start Date ^ICMJE

May 2009

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

The Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Impaired Glucose Tolerance

Official Title ^ICMJE

Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Type 2 Diabetes or Impaired Glucose Tolerance

Brief Summary

To study the effect of cinnamon on postprandial blood glucose, and plasma concentrations of insulin in subjects with impaired glucose tolerance.

Detailed Description

Ten subjects with impaired glucose tolerance were assessed in a crossover trial. A standard 75 g oral glucose tolerance test (OGTT) was served with placebo or cinnamon capsules. Finger-prick capillary and venous blood samples were taken before and 15, 30, 45, 60, 90, 120, 150, and 180 min after the start of the OGTT to measure glucose, and insulin.

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Case-Crossover
Time Perspective: Cross-Sectional

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Probability Sample

Study Population

All subjects were recruited from the population in southern Sweden.

Condition ^ICMJE

Diabetes

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

September 2009

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patients were selected for the study on the basis of the following inclusion criteria: diagnosis of impaired glucose tolerance for < 12 months before enrollment. Glucose tolerance status and fasting blood glucose levels were evaluated using the criteria established by the American Diabetes Association.

Exclusion Criteria:

Subjects who had thyroid disorders, or used insulin, oral hypoglycemics, and insulin-sensitizing drugs within 60 days before enrollment were excluded.

Gender

Both

Ages

18 Years to 80 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Not Provided

Administrative Information

NCT Number ^ICMJE

NCT01027585

Other Study ID Numbers ^ICMJE

353/2008a

Has Data Monitoring Committee

Yes

Responsible Party

Lars Stavenow, Departments of Medicine, Malmö University Hospital

Study Sponsor ^ICMJE

Skane University Hospital

Collaborators ^ICMJE

Lund University

Investigators ^ICMJE

Principal Investigator:

Joanna Hlebowicz, MD, PhD

Skane University Hospital

Information Provided By

Skane University Hospital

Verification Date

May 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top